Cancer Gene Discovery and Molecular Validation Unit
The Cancer Gene Discovery and Molecular Validation Unit is where molecular genetics in cancer research is performed to identify new biological factors contributing to tumor formation and progression. Sophisticated experimental protocols are executed by expert technical staff and talented research fellows to generate vast amounts of genomic data in an effort to make inferences between genomic rearrangements and cancer development. The unit hopes to generate molecular signatures of cancer progression and response to therapy based on somatic mutation status, gene expression profiling, comparative genomic hybridization and epigenomics across multiple tumor types to keep in line with TGen's mission of early diagnostics and smarter drugs. Furthermore, there will be provisions for standardized and reproducible validation assays to characterize novel biomarkers in clinical cancer specimens. Currently, major initiatives are underway or have been planned in the areas of prostate cancer, melanoma, breast cancer, colorectal cancer, and multiple myeloma.
Current Projects:
1. Identifying hereditary prostate cancer genes
2. Discovering the natural history of melanoma
Staff:
John Carpten Ph.D., Division Director
Michael Bittner, Ph.D., Senior Investigator
Galen Hostetter, M.D., Associate Investigator
Kevin Brown, Ph.D., Associate Investigator
Ingrid Hedenfalk, Ph.D., Visiting Investigator
Edward Dougherty, Ph.D., Adjunct Faculty
|
E-MAIL THIS ARTICLE
PRINT THIS PAGE
Podcasts
NewsFeed